Cargando...
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
Romidepsin is a histone deacetylase inhibitor (HDI), approved by the US FDA for the treatment of cutaneous T-cell lymphoma (CTCL). Although various mechanisms have been proposed for the activity of HDls, including induction of genes controlling cell cycle, acetylation of cytoplasmic proteins and dir...
Gardado en:
| Publicado en: | Expert Rev Anticancer Ther |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2010
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6361116/ https://ncbi.nlm.nih.gov/pubmed/20645688 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/era.10.88 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|